Integrating Newer Therapies into Management of Adult ALL

EP. 1: Prognostic Factors Which Impact ALL Management

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

EP. 2: Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

EP. 3: Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

EP. 4: Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 21st 2021

EP. 5: Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

EP. 6: Role of MRD Testing in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

EP. 7: Treatment of Acute Lymphoblastic Leukemia in the Community Setting

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

EP. 8: Managing MRD-Positive Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

EP. 9: Managing MRD-Negative Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

EP. 10: Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

EP. 11: Approach to Managing Relapsed Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

EP. 12: CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

EP. 13: CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

EP. 14: Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

EP. 15: Evolving Field of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

EP. 16: ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

EP. 1: Prognostic Factors Which Impact ALL Management

EP. 2: Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

EP. 3: Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

EP. 4: Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

EP. 5: Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

EP. 6: Role of MRD Testing in Acute Lymphoblastic Leukemia

EP. 7: Treatment of Acute Lymphoblastic Leukemia in the Community Setting

EP. 8: Managing MRD-Positive Acute Lymphoblastic Leukemia

EP. 9: Managing MRD-Negative Acute Lymphoblastic Leukemia

EP. 10: Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

EP. 11: Approach to Managing Relapsed Acute Lymphoblastic Leukemia

EP. 12: CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

EP. 13: CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

EP. 14: Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

EP. 15: Evolving Field of Acute Lymphoblastic Leukemia

EP. 16: ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Trending on OncLive

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC

Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC

Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC

FDA Flashback: Breast Cancer Decisions and News From June 2026